DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ZTTK syndrome — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleZTTK syndrome maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for zttk syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
acetyl-CoA acetyltransferase 2 (ACAT2) — ACAT2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet coadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1WL4 · 1.55 Å · ligand COENZYME A (COA). Experimental structure, not a prediction.
What the evidence adds up to
ZTTK syndrome is a rare multisystemic congenital disorder caused by heterozygous variants in the SON gene. In one case, a small-for-date infant with gastrointestinal bleeding, developmental delay, and thrombocytopenia was found by next-generation sequencing to carry a de novo heterozygous c.5751_5754del variant in SON, resulting in a frameshift p.V1918Efs*87. The same variant was absent in both parents. That finding enriched the mutational spectrum of the SON gene and provided a basis for genetic counselling, but no treatment or outcome data were reported.
A separate 2025 case described an 11-year-old boy with hypotonia, poor growth, short stature, microcephaly, developmental delay, seizures, hydrocephalus, brain abnormalities, strabismus, urinary problems, and facial dysmorphism. He also had a history of stroke, obsession, insomnia, self-injurious behaviour, and hearing loss. Whole exome sequencing identified a novel de novo SON gene variant, confirmed by Sanger sequencing, with both parents testing normal. The authors noted that stroke and recurrent urolithiasis are rarely reported features in ZTTK syndrome. Again, no therapeutic intervention or outcome was described.
No clinical trial, no drug, no survival or response rate data exist for ZTTK syndrome in these abstracts. The literature consists entirely of single-case genetic reports. What is missing is any systematic natural history study, any patient registry with longitudinal follow-up, any preclinical model for drug screening, and any funding for a clinical trial. Without a defined patient population and measurable endpoints, repurposing cannot begin.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2022 · 3 citations
[Clinical and genetic analysis of a child with ZTTK syndrome due to heterozygous variant of SON gene].
AbstractOBJECTIVE: To explore the genetic etiology of a small-for-date infant with gastrointestinal bleeding, developmental delay and thrombocytopenia (Zhu-Tokita-Takenouchi-Kim syndrome). METHODS: Clinical and laboratory examinations were carried out for the patient. Next-generation sequencing (NGS) was used to detect potential variant associated with the disease. Candidate variant was verified by Sanger sequencing of the child and her parents. RESULTS: NGS revealed that the child has carried a heterozygous c.5751_5754del variant of the SON gene, which resulted in a frameshift p.V1918Efs*87. The same variant was detected in neither parent. CONCLUSION: The heterozygous variant of SON gene probably underlay the ZTTK syndrome in this child. Above finding has enriched the mutational spectrum of the SON gene and provides a basis for genetic counseling and clinical decision-making.
Supplementary Material for: A Novel SON Gene Variant Associated with Rare Clinical Features in ZTTK Syndrome: A Case Report and Literature Review
AbstractIntroduction: ZTTK syndrome is a rare multisystemic congenital disorder caused by SON gene variants. This study aimed to present the results of whole exome sequencing, and describe some rare findings observed in the proband. Case Presentation: An 11-year-old boy exhibited hypotonia, poor growth, short stature, and microcephaly. The patient displayed various neurological symptoms, such as developmental delay, seizures, hydrocephalus, and brain abnormalities. He presented with strabismus, urinary problems, and facial dysmorphism. A history of stroke, obsession, insomnia, self-injurious behavior, and hearing loss, were also noted. Based on the patient's clinical findings, whole exome sequencing was performed. A novel variant in the SON gene was identified. This variant was confirmed by Sanger sequencing. Notably, the parents tested normal for the variant. Conclusion: This study presents a patient who exhibited a wide range of behavioral abnormalities, stroke, and recurrent urolithiasis — features that are rarely reported in ZTTK syndrome — and includes a review of the literature.
Supplementary Material for: A Novel SON Gene Variant Associated with Rare Clinical Features in ZTTK Syndrome: A Case Report and Literature Review
AbstractIntroduction: ZTTK syndrome is a rare multisystemic congenital disorder caused by SON gene variants. This study aimed to present the results of whole exome sequencing, and describe some rare findings observed in the proband. Case Presentation: An 11-year-old boy exhibited hypotonia, poor growth, short stature, and microcephaly. The patient displayed various neurological symptoms, such as developmental delay, seizures, hydrocephalus, and brain abnormalities. He presented with strabismus, urinary problems, and facial dysmorphism. A history of stroke, obsession, insomnia, self-injurious behavior, and hearing loss, were also noted. Based on the patient's clinical findings, whole exome sequencing was performed. A novel variant in the SON gene was identified. This variant was confirmed by Sanger sequencing. Notably, the parents tested normal for the variant. Conclusion: This study presents a patient who exhibited a wide range of behavioral abnormalities, stroke, and recurrent urolithiasis — features that are rarely reported in ZTTK syndrome — and includes a review of the literature.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
